Clinical Trial Update: Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of a tetravalent dengue vaccine in HIV-positive adults; results completed and posted in July 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever
• Dengue Hemorrhagic Fever

Drugs mentioned

• Dengvaxia (CYD-TDV)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Status: COMPLETED | Results posted: 2024-07-19